On Nov. 23, 2020, Merck, known as MSD outside the U.S. and Canada, announced the company had submitted applications to the U.S. FDA and EMA for licensure of V114, Merckﾒs investigational 15-valent pneumococcal conjugate vaccine, for use in adults 18 years of age and older.